Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader-Willi Syndrome Patients: A Cohort Study.
Prader–Willi Syndrome
adaptive behavior
cognition
growth hormone treatment
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 Mar 2022
14 Mar 2022
Historique:
received:
17
02
2022
revised:
06
03
2022
accepted:
12
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Prader-Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2). We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests. Group 1 ( Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels.
Sections du résumé
BACKGROUND
BACKGROUND
Prader-Willi Syndrome (PWS) is a genetically based neurodevelopmental disease characterized by obesity, hyperphagia, and mild to moderate intellectual disability. Treatment with growth hormone (GH) could provide cognitive benefits. The objective of the present study was to compare the cognitive and adaptive performance of 31 patients with genetically confirmed PWS grouped in two cohorts, one treated with GH before 2 years old (Group 1) and the other receiving the treatment later (Group 2).
METHOD
METHODS
We compared two variables necessary to diagnose intellectual disability: intellectual performance, using the Weschler scales, and adaptive behavior, using the DABS scale. The scores were analyzed by means of non-parametric statistical tests.
RESULTS
RESULTS
Group 1 (
CONCLUSIONS
CONCLUSIONS
Treatment with GH should be administered in the early stage of development (before 2 years old) to obtain greater benefits at the cognitive and adaptive levels.
Identifiants
pubmed: 35329918
pii: jcm11061592
doi: 10.3390/jcm11061592
pmc: PMC8955812
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Curr Opin Psychiatry. 2015 Mar;28(2):102-6
pubmed: 25599341
Orphanet J Rare Dis. 2020 Feb 21;15(1):55
pubmed: 32085791
Acta Paediatr. 2015 Jan;104(1):59-67
pubmed: 25263744
Pediatrics. 2002 Feb;109(2):E35
pubmed: 11826245
Orphanet J Rare Dis. 2016 Nov 16;11(1):153
pubmed: 27852283
Eur J Endocrinol. 2020 Apr;182(4):405-411
pubmed: 31961800
J Intellect Disabil Res. 2005 Apr;49(Pt 4):245-52
pubmed: 15816811
J Commun Disord. 2013 Mar-Apr;46(2):193-201
pubmed: 23295077
Eur Child Adolesc Psychiatry. 2015 Sep;24(9):1091-101
pubmed: 25522840
Eur J Endocrinol. 2020 Jun;182(6):C21-C25
pubmed: 32240979
Neurosci Biobehav Rev. 2017 Jan;72:153-167
pubmed: 27836461
PLoS One. 2019 Oct 17;14(10):e0223162
pubmed: 31622356
J Intellect Disabil Res. 2007 Apr;51(Pt 4):302-11
pubmed: 17326811
Int J Mol Sci. 2018 Jan 26;19(2):
pubmed: 29373545
Orphanet J Rare Dis. 2019 Nov 4;14(1):238
pubmed: 31684997
Endocrinol Diabetes Nutr (Engl Ed). 2018 Apr;65(4):229-236
pubmed: 29510967
J Clin Endocrinol Metab. 2012 Jul;97(7):2307-14
pubmed: 22508707
J Intellect Disabil Res. 2010 Mar;54(3):204-15
pubmed: 20136683
Endocrine. 2021 Feb;71(2):321-330
pubmed: 33222122
J Pediatr Endocrinol Metab. 2019 Aug 27;32(8):879-884
pubmed: 31271556